Monday, November 29, 2021

Source of medical information and behavioral seeking patterns in patients affected with Friedreich's ataxia and their caregivers: a survey study

›
Miele G, Lavorgna L, De Mercanti SF, Iudicello M, Abbadessa G, Matta M, Bonavita S, Clerico M.; Neurol Sci. 2021 Nov 28. doi: 10.1007/s10072...
Tuesday, November 23, 2021

Diagnosis and Management of Cardiovascular Involvement in Friedreich Ataxia

›
Emanuele Monda, Michele Lioncino, Marta Rubino, Silvia Passantino, Federica Verrillo, Martina Caiazza, Annapaola Cirillo, Adelaide Fusco, Fr...
Monday, November 22, 2021

Cellular pathophysiology of Friedreich's ataxia cardiomyopathy

›
Jarmon G. Lees, Marek Napierala, Alice Pébay, Mirella Dottori, Shiang Y. Lim; International Journal of Cardiology, 2021, doi:10.1016/j.ijcar...
Friday, November 19, 2021

Exicure, Inc. Reports Third Quarter 2021 Financial Results and Corporate Progress

›
Published : Friday, November 19, 2021, ACROFAN=Businesswire.  XCUR-FXN–Friedreich’s Ataxia Exicure remains committed to maintaining its dev...

Reata Pharmaceuticals Receives Fast Track Designation From the FDA for Omaveloxolone for the Treatment of Friedreich’s Ataxia

›
November 18, 2021, PLANO, Texas--(BUSINESS WIRE)--Reata Pharmaceuticals, today announced the U.S. Food and Drug Administration (“FDA”) has g...
Thursday, November 18, 2021

Body Mass Index and Height in Friedreich Ataxia What Do We Know?

›
Sylvia M. Boesch, Elisabetta Indelicato; Neurol Genet Dec 2021, 7 (6) e637; DOI: 10.1212/NXG.0000000000000637  In this issue of Neurology® G...
Tuesday, November 16, 2021

STEALTH BIOTHERAPEUTICS REPORTS THIRD QUARTER 2021 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS

›
11/12/2021. MarketScreener. Friedreich's ataxia. The investigator is awaiting Institutional Review Board approval of the planned Phase 2...

Larimar expects to initiate its Jive open-label extension and pediatric multiple ascending dose trials in the first half of next year.

›
BALA CYNWYD, Pa., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”), a clinical-stage biotechnology company focused o...
Sunday, November 14, 2021

Body Mass Index and Height in the Friedreich Ataxia Clinical Outcome Measures Study

›
Maya Patel, Ashley McCormick, Jaclyn Tamaroff, Julia Dunn, Jonathan A. Mitchell, Kimberly Y. Lin, Jennifer Farmer, Christian Rummey, Susan L...
Saturday, November 13, 2021

Friedreich's ataxia. The investigator is awaiting Institutional Review Board approval of the planned Phase 2a clinical trial in patients with Friedreich's ataxia and expects to begin enrollment in early 2022.

›
BOSTON, Nov. 11, 2021 /PRNewswire/ -- Stealth Biotherapeutics (Nasdaq:MITO), a clinical-stage biotechnology company focused on the discovery...